This free sheet contains 100 accelerators and incubators you can apply to today, along with information about the industries they generally invest in.
This free sheet contains all the information about the top 100 unicorns, including their valuation, HQ's location, founded year, name of founders, funding amount and number of employees.
This free Notion document contains the best 100+ resources you need for building a successful startup, divided in 4 categories: Fundraising, People, Product, and Growth.
The biotechnology industry is expanding into new fields, from neurotechnology to food production. This growth is supported by large funding rounds for both new and established companies.
Neuralink is developing brain-computer interfaces with $1.3B in funding. Avenzo Therapeutics, founded in 2022, has already secured $841.9M for its cancer treatments.
Below is our list of 100 Biotechnology startups worth keeping an eye on.
Everything you need to raise funding for your startup, including 3,500+ investors, 7 tools, 18 templates and 3 learning resources.
Buy It For $97 $297 →Information about the industries, countries, and cities they generally invest in.
Get the Sheet for $50Information about their valuation, HQ's location, founded year, name of founders, funding amount and number of employees.
Get the Sheet for $50List of startup investors in the BioTech, Health, and Medicine industries, along with their Twitter, LinkedIn, and email addresses.
Get the Sheet for $50List of 250 startup investors in the AI and Machine Learning industries, along with their Twitter, LinkedIn, and email addresses.
Get the Sheet for $50List of 250 startup investors in the FinTech and Finance industries, along with their Twitter, LinkedIn, and email addresses.
Get the Sheet for $50Neuralink builds implantable brain-computer interfaces that aim to give people with paralysis the ability to control devices with their thoughts. Their neurotechnology is designed to create a direct communication link between the human brain and computers to address various neurological conditions.
Colossal Biosciences is pioneering the field of de-extinction through advanced biotechnology and genetic engineering. Their team uses cutting-edge gene editing tools to resurrect species like the woolly mammoth and restore lost biodiversity.
Odyssey Therapeutics develops precision immunomodulators and oncology medicines for patients with cancer and inflammatory diseases. Their work is driven by a proprietary platform that integrates genomics, biology, and chemistry to discover novel treatments.
Revyve produces texturizing ingredients from yeast that are engineered to replicate the function of eggs in various food categories. Their technology offers food companies a sustainable, animal-free ingredient to use in both new and existing product lines.
Enveda Biosciences builds a drug discovery platform that maps the chemistry of the natural world. The company uses machine learning and metabolomics to find and develop novel medications derived from plants.
Insilico Medicine is using artificial intelligence to reinvent the pharmaceutical industry's approach to drug discovery. Their end-to-end platform helps researchers identify new disease targets and design novel therapeutics for cancer and age-related illnesses.
Avenzo Therapeutics develops specialized oncology therapies for cancer treatment. They are advancing a portfolio of drug candidates to address cancers with significant unmet medical needs.
Character Biosciences develops a discovery engine that integrates genomics, clinical data, and machine learning to identify novel therapeutics for diseases of aging. Their initial work targets the development of new treatments for age-related macular degeneration.
CHARM Therapeutics applies its 3D deep learning technology to discover and develop small-molecule medicines for challenging diseases. They are advancing a pipeline of therapeutics that target the interaction between menin and the KMT2A protein, a key driver in certain cancers.
Cartography Biosciences is developing a new class of cancer immunotherapies based on mapping novel tumor antigens. This approach allows them to create highly specific treatments designed to be more effective for oncology patients.
The top 10 are just a small slice of what’s happening in biotechnology right now. Founders across the board are raising serious capital, with total funding for these companies reaching well into the billions.
Some are early in their journey while others are scaling quickly, applying biotech to everything from medicine to fashion. Here’s a look at the other companies shaping the biotechnology landscape in 2026.
| Startup | Main Industry | Year Founded | Amount Raised | Last Funding Round |
|---|---|---|---|---|
| AI | 2021 | $601.7M | Venture Round | |
| Biotech | 2022 | $6.9M | Seed | |
| Biotech | 2018 | $97M | Series B | |
| Biotech | 2007 | $496.4M | Series D | |
| Fashion | 2019 | $86.2M | Venture Round | |
| Biotech | 2021 | $1.1B | Series A | |
| Biotech | 2017 | $678M | Series D | |
| Fashion | 2017 | $94.7M | Series C | |
| Biotech | 2019 | $921.3M | Series D | |
| AgTech | 2011 | $616.9M | Series D | |
| Biotech | 2023 | $19.5M | Seed | |
| AgTech | 2018 | $72.1M | Series A | |
| AI | 2015 | $23.8M | Series B | |
| Biotech | 2019 | $7.6M | Grant | |
| Biotech | 2013 | $156.3M | Series B | |
| Biotech | 2016 | $600M | Venture Round | |
| Fashion | 2016 | $46.6M | Series A | |
| Biotech | 2021 | $65M | Series A | |
| Biotech | 2021 | $45.8M | Series A | |
| Food | 2018 | $42M | Series A | |
| Biotech | 1961 | $210M | Debt Financing | |
| AI | 2009 | $108.1M | Grant | |
| Biotech | 2019 | $6.2M | Series A | |
| AI | 2017 | $98M | Venture Round | |
| AI | 2022 | $103.1M | Series A | |
| Biotech | 2021 | $54.1M | Series B | |
| Biotech | 2009 | $472.6M | Series H | |
| Biotech | 2016 | $181.2M | Venture Round | |
| Biotech | 2019 | $332M | Venture Round | |
| Biotech | 1908 | $450M | Private Equity | |
| Biotech | 2018 | $39.4M | Series A | |
| Biotech | 2015 | $30.2M | Series A | |
| Biotech | 2016 | $150.1M | Series C | |
| AI | 2023 | $13M | Seed | |
| Biotech | 2010 | $78.5M | Venture Round | |
| Biotech | 2015 | $7.6M | Series A | |
| Biotech | 2019 | $355M | Series C | |
| Biotech | 2014 | $1.5B | Corporate Round | |
| AI | 2014 | $129.8M | Series D | |
| Biotech | 2016 | $425.9M | Series D | |
| Biotech | 2021 | $61.8M | Series A | |
| Data | 2015 | $403M | Series C | |
| AI | 2024 | $76M | Series A | |
| Biotech | 2020 | $19M | Series A | |
| Biotech | 2014 | $456M | Series D | |
| Biotech | 2019 | $69.6M | Series B | |
| Biotech | 2018 | $127.3M | Series B | |
| Biotech | 2019 | $258M | Venture Round | |
| Biotech | 2015 | $118.8M | Debt Financing | |
| Biotech | 2017 | $257.2M | Series B | |
| Biotech | 2020 | $180M | Venture Round | |
| Biotech | 2016 | $40M | Series A | |
| Biotech | 2024 | $25M | Seed | |
| Biotech | 2023 | $28.6M | Series A | |
| Biotech | 2019 | $237M | Series B | |
| Healthcare | 2016 | $154.1M | Series C | |
| Biotech | 2021 | $180M | Angel | |
| Analytics | 2017 | $41.4M | Series A | |
| AI | 2017 | $120.8M | Grant | |
| Biotech | 2017 | $120M | Convertible Note | |
| Biotech | 2021 | $79.5M | Grant | |
| Biotech | 2013 | $25.7M | Venture Round | |
| Biotech | 2021 | $38M | Series B | |
| Biotech | 2018 | $13M | Seed | |
| Biotech | 2018 | $287M | Series C | |
| AI | 2022 | $42M | Series A | |
| Biotech | 2017 | $1.1B | Grant | |
| Biotech | 2012 | $1B | Series C | |
| Biotech | 2022 | $45.5M | Series A | |
| Biotech | 2024 | $50M | Series A | |
| Healthcare | 2022 | $270M | Series A | |
| AgTech | 2016 | $753M | Series G | |
| Biotech | 2020 | $46M | Series A | |
| Biotech | 2020 | $13.8M | Grant | |
| Biotech | 2018 | $640.6M | Series D | |
| Biotech | 2007 | $43.4M | Debt Financing | |
| Analytics | 2018 | $300M | Series C | |
| Biotech | 2013 | $271.3M | Series F | |
| Biotech | 2020 | $19M | Series A | |
| Biotech | 2007 | $28.1M | Series C | |
| Biotech | 2009 | $51.9M | Series B | |
| Biotech | 2019 | $117.6M | Series A | |
| Healthcare | 2014 | $227M | Series D | |
| Biotech | 2018 | $346.1M | Series D | |
| Biotech | 2011 | $8.7M | Series A | |
| Biotech | 2021 | $3B | Series A | |
| Biotech | 2018 | $66.5M | Series B | |
| Biotech | 2020 | $2.5B | Grant | |
| AI | — | $26M | Seed | |
| Biotech | 2019 | $175.9M | Undisclosed |
